MA45620A - Oligonucléotides antisens pour la modulation de l'expression de htra1 - Google Patents

Oligonucléotides antisens pour la modulation de l'expression de htra1

Info

Publication number
MA45620A
MA45620A MA045620A MA45620A MA45620A MA 45620 A MA45620 A MA 45620A MA 045620 A MA045620 A MA 045620A MA 45620 A MA45620 A MA 45620A MA 45620 A MA45620 A MA 45620A
Authority
MA
Morocco
Prior art keywords
modulation
oligonucleotides
antisens
htra1
expression
Prior art date
Application number
MA045620A
Other languages
English (en)
Inventor
Peter Hagedorn
Heidi Hudlebusch
Roberto Iacone
Susanne Kammler
Søren Ottosen
Lykke Pedersen
Sindri Traustason
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA45620A publication Critical patent/MA45620A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des oligonucléotides antisens (oligomères) complémentaires de htra1, conduisant à une modulation de l'expression de htra1. La modulation de l'expression de htra est bénéfique pour une gamme de troubles médicaux, tels que la dégénérescence maculaire, par exemple. Dégénérescence maculaire liée à l'âge.
MA045620A 2016-07-01 2017-06-28 Oligonucléotides antisens pour la modulation de l'expression de htra1 MA45620A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177508 2016-07-01
EP17170129 2017-05-09

Publications (1)

Publication Number Publication Date
MA45620A true MA45620A (fr) 2019-05-08

Family

ID=59295175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045620A MA45620A (fr) 2016-07-01 2017-06-28 Oligonucléotides antisens pour la modulation de l'expression de htra1

Country Status (21)

Country Link
US (2) US10519450B2 (fr)
EP (1) EP3478839A1 (fr)
JP (3) JP7060525B2 (fr)
KR (1) KR20190025970A (fr)
CN (2) CN118325897A (fr)
AU (1) AU2017289204A1 (fr)
BR (1) BR112018077321A2 (fr)
CA (1) CA3026855A1 (fr)
CL (1) CL2018003698A1 (fr)
CO (1) CO2018013240A2 (fr)
CR (1) CR20180606A (fr)
IL (1) IL263489A (fr)
MA (1) MA45620A (fr)
MX (1) MX2018015722A (fr)
PE (1) PE20190381A1 (fr)
PH (1) PH12018502707A1 (fr)
RU (1) RU2019101298A (fr)
SG (2) SG10202005885VA (fr)
TW (1) TW201803990A (fr)
WO (1) WO2018002105A1 (fr)
ZA (1) ZA201808291B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3472151A4 (fr) 2016-06-21 2020-03-04 Orion Ophthalmology LLC Dérivés de prolinamide carbocycliques
EP4257191A3 (fr) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Dérivés hétérocycliques de prolinamide
CA3026855A1 (fr) 2016-07-01 2018-01-04 F. Hoffmann-La Roche Ag Oligonucleotides antisens pour la modulation de l'expression de htra1
WO2019122277A1 (fr) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Nouvelles thiophosphoramidites
EP3728591A1 (fr) 2017-12-22 2020-10-28 Roche Innovation Center Copenhagen A/S Oligonucléotides gapmères comprenant une liaison internucléosidique phosphorodithioate
CN111757936A (zh) 2017-12-22 2020-10-09 罗氏创新中心哥本哈根有限公司 包含二硫代磷酸酯核苷间连接的寡核苷酸
US11332733B2 (en) 2018-02-12 2022-05-17 lonis Pharmaceuticals, Inc. Modified compounds and uses thereof
WO2020007772A1 (fr) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Oligonucléotides antisens ciblant gbp-1
WO2020109344A1 (fr) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Dispositif d'administration oculaire pour oligonucléotides antisens
WO2020109343A1 (fr) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Polythérapie pour le traitement de la dégénérescence maculaire

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
WO2000008134A2 (fr) 1998-08-03 2000-02-17 Novartis Ag SERINE PROTEASE DE HtrA HUMAINE
RU2233844C2 (ru) 1999-02-12 2004-08-10 Санкио Компани Лимитед Новые нуклеозидные и олигонуклеотидные аналоги
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
EP2141233B1 (fr) 2002-11-18 2016-10-19 Roche Innovation Center Copenhagen A/S Conception antisens
CA2609180A1 (fr) 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Compositions et utilisations dans la lmw-ptpase
WO2007031091A2 (fr) 2005-09-15 2007-03-22 Santaris Pharma A/S Composes antagonistes d'arn de modulation de l'expression de p21 ras
AU2007211080B9 (en) 2006-01-27 2012-05-03 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
JP2009544317A (ja) 2006-07-26 2009-12-17 イェール ユニバーシティー 加齢性黄斑変性の診断および治療
EP2081596A4 (fr) 2006-10-06 2010-07-21 Univ Utah Res Found Procede de detection de maladies et d'affections pathologiques de l' il et traitement de celles-ci
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
AU2008260277C1 (en) 2007-05-30 2014-04-17 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
TW200911290A (en) 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
DK2176280T4 (en) 2007-07-05 2015-07-20 Isis Pharmaceuticals Inc 6-Disubstituerede bicykliske nukleinsyreanaloge
WO2009059321A2 (fr) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Analyse de lieu de rca pour estimer la sensibilité à l'amd et au mpgnii
WO2009067647A1 (fr) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2580228B1 (fr) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. 2' amino- et 2' thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers
FR2965278B1 (fr) 2010-09-23 2014-10-10 Univ Caen Basse Normandie Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations
US9751909B2 (en) 2011-09-07 2017-09-05 Marina Biotech, Inc. Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
WO2013154798A1 (fr) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Analogues tricycliques d'acide nucléique
EP2850184A4 (fr) 2012-05-16 2016-01-27 Rana Therapeutics Inc Compositions et méthodes pour moduler l'expression génique
JP6452614B2 (ja) 2012-11-15 2019-01-16 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドコンジュゲート
IL295097A (en) 2015-10-30 2022-09-01 Genentech Inc Anti-htra1 antibodies and methods of using them
CA3026855A1 (fr) 2016-07-01 2018-01-04 F. Hoffmann-La Roche Ag Oligonucleotides antisens pour la modulation de l'expression de htra1
WO2018087200A1 (fr) 2016-11-11 2018-05-17 Roche Innovation Center Copenhagen A/S Capture et détection d'oligonucléotides thérapeutiques
US20190055564A1 (en) 2017-06-01 2019-02-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression

Also Published As

Publication number Publication date
PH12018502707A1 (en) 2019-11-11
CR20180606A (es) 2019-02-14
EP3478839A1 (fr) 2019-05-08
CL2018003698A1 (es) 2019-04-05
CA3026855A1 (fr) 2018-01-04
US20200399641A1 (en) 2020-12-24
CO2018013240A2 (es) 2018-12-14
SG11201811554SA (en) 2019-01-30
JP2024029178A (ja) 2024-03-05
IL263489A (en) 2019-01-31
JP7060525B2 (ja) 2022-04-26
RU2019101298A3 (fr) 2021-01-26
KR20190025970A (ko) 2019-03-12
JP7416852B2 (ja) 2024-01-17
MX2018015722A (es) 2019-05-27
WO2018002105A1 (fr) 2018-01-04
PE20190381A1 (es) 2019-03-08
BR112018077321A2 (pt) 2019-04-24
AU2017289204A1 (en) 2019-01-17
SG10202005885VA (en) 2020-07-29
JP2019522987A (ja) 2019-08-22
ZA201808291B (en) 2019-10-30
US20180002701A1 (en) 2018-01-04
RU2019101298A (ru) 2020-08-03
JP2022106785A (ja) 2022-07-20
US10519450B2 (en) 2019-12-31
CN109415732A (zh) 2019-03-01
CN118325897A (zh) 2024-07-12
TW201803990A (zh) 2018-02-01
CN109415732B (zh) 2024-01-02

Similar Documents

Publication Publication Date Title
MA45620A (fr) Oligonucléotides antisens pour la modulation de l'expression de htra1
PH12021551065A1 (en) Fused ring compounds
PH12018501268A1 (en) Compounds useful as kinase inhibitors
GEP20217281B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
ECSP20075270A (es) Compuestos
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA40895B1 (fr) Synthèse de copanlisib et son sel de dichlorhydrate
PH12019502636A1 (en) Antisense oligonucleotides for modulating htra1 expression
BR112019005886A2 (pt) tratamento com água de material lipídico
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MX2019007103A (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
BR112021017661A2 (pt) Uso de compostos 8,9-di-hidrocanabidiol
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
BR112015031945A2 (pt) processos para a preparação de compostos
MX2022013814A (es) Tratamiento de infecciones virales.
FR3078704B1 (fr) Derives d'isohexide et leurs utilisations
MA43507B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA42296B1 (fr) Composés antibactériens
AR112908A1 (es) Oligonucleótidos antisentido para modular la expresión de htra1
CO2022009260A2 (es) Composiciones farmacéuticas oftálmicas
MX2022005502A (es) Purificacion de proteinas.